4-(2,3-dimethoxyphenyl)-5-cyano-2H-1,2,3-triazole | 928206-96-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 4-(2,3-dimethoxyphenyl)-5-cyano-2H-1,2,3-triazole
• 英文别名: 5-(2,3-dimethoxyphenyl)-2H-triazole-4-carbonitrile
• CAS: 928206-96-6
• 化学式: C₁₁H₁₀N₄O₂
• 分子量: 230.226
• InChiKey: NSQUWOUGEKUVKL-UHFFFAOYSA-N

物化性质

• 熔点：
  179-180 °C
• 沸点：
  428.7±45.0 °C(Predicted)
• 密度：
  1.35±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  17
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.18
• 拓扑面积：
  83.8
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  3-(2,3-dimethoxyphenyl)propynenitrile 在 sodium azide 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 1.5h， 以60%的产率得到4-(2,3-dimethoxyphenyl)-5-cyano-2H-1,2,3-triazole
  参考文献：
  名称：

  Synthesis and biological evaluation of 4-aryl-5-cyano-2H-1,2,3-triazoles as inhibitor of HER2 tyrosine kinase

  摘要：

  4-Aryl-5-cyano-2H-1,2,3-triazoles bearing a variety of substituting groups on 4-phenyl were synthesized. The chemicals, designed as HER2 tyrosine kinase inhibitors, were screened for bioactivity of inhibiting growth of breast cancer MDA-MB-453 cells. The lowest IC50 value of inhibiting HER2 tyrosine kinase phosphorylation in breast cancer cells is 6.6 mu M and the IC50 value of cell growth inhibition is correspondingly 30.9 mu M. The lipophilicity of substituting groups on triazoles is the main factor to influence their bioactivities. (c) 2006 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2006.09.041

文献信息

• CYANOTRIAZOLE COMPOUNDS
  申请人：OTSUKA PHARMACEUTICAL CO., LTD.

  公开号：US20160229816A1

  公开（公告）日：2016-08-11

  This invention relates to a cyanotriazole compound represented by the formula (1): wherein each symbols are defined in the specification, or a salt thereof. The compound or a salt thereof stimulates the citric acid cycle activity and/or improves hyperglycemia with less side effects, and excellent safety, and therefore, it is useful for treating and/or preventing diseases or disorders on which citric acid cycle activation and/or improvement of hyperglycemia has a prophylactic and/or therapeutic effect, for example, diabetes, impaired glucose tolerance, insulin resistance, diabetic complications, obesity, dyslipidemia, hepatic steatosis, atherosclerosis and/or cardiovascular disease, as well as diseases or disorders that would benefit from stimulating energy expenditure.

  本发明涉及一种由式（1）表示的氰基三唑化合物，其中每个符号在规范中有定义，或其盐。该化合物或其盐刺激柠檬酸循环活性和/或改善高血糖症的副作用较小，安全性优异，因此，它对于治疗和/或预防柠檬酸循环激活和/或改善高血糖症具有预防和/或治疗作用的疾病或疾病具有用处，例如糖尿病、糖耐量受损、胰岛素抵抗、糖尿病并发症、肥胖症、血脂异常、脂肪肝、动脉粥样硬化和/或心血管疾病，以及那些从刺激能量消耗中受益的疾病或疾病。
• Cyanotriazole compounds
  申请人：OTSUKA PHARMACEUTICAL CO., LTD.

  公开号：US10626095B2

  公开（公告）日：2020-04-21

  This invention relates to a cyanotriazole compound represented by the formula (1): wherein each symbols are defined in the specification, or a salt thereof. The compound or a salt thereof stimulates the citric acid cycle activity and/or improves hyperglycemia with less side effects, and excellent safety, and therefore, it is useful for treating and/or preventing diseases or disorders on which citric acid cycle activation and/or improvement of hyperglycemia has a prophylactic and/or therapeutic effect, for example, diabetes, impaired glucose tolerance, insulin resistance, diabetic complications, obesity, dyslipidemia, hepatic steatosis, atherosclerosis and/or cardiovascular disease, as well as diseases or disorders that would benefit from stimulating energy expenditure.

  本发明涉及一种由式（1）表示的氰三唑化合物： 其中各符号在说明书中定义，或其盐。该化合物或其盐可刺激柠檬酸循环活性和/或改善高血糖，且副作用小、安全性高，因此可用于治疗和/或预防柠檬酸循环激活和/或改善高血糖具有预防和/或治疗作用的疾病或紊乱、例如，糖尿病、糖耐量受损、胰岛素抵抗、糖尿病并发症、肥胖症、血脂异常、肝脂肪变性、动脉粥样硬化和/或心血管疾病，以及可从刺激能量消耗中获益的疾病或紊乱。
• Synthesis and biological evaluation of 4-aryl-5-cyano-2H-1,2,3-triazoles as inhibitor of HER2 tyrosine kinase
  作者：Zhi-Yi Cheng、Wen-Jie Li、Feng He、Jun-Min Zhou、Xiao-Feng Zhu

  DOI：10.1016/j.bmc.2006.09.041

  日期：2007.2.1

  4-Aryl-5-cyano-2H-1,2,3-triazoles bearing a variety of substituting groups on 4-phenyl were synthesized. The chemicals, designed as HER2 tyrosine kinase inhibitors, were screened for bioactivity of inhibiting growth of breast cancer MDA-MB-453 cells. The lowest IC50 value of inhibiting HER2 tyrosine kinase phosphorylation in breast cancer cells is 6.6 mu M and the IC50 value of cell growth inhibition is correspondingly 30.9 mu M. The lipophilicity of substituting groups on triazoles is the main factor to influence their bioactivities. (c) 2006 Elsevier Ltd. All rights reserved.